KR20190124074A - Composition containing Berberis amurensis extracts for preventing the formation of biofilm of microorganism - Google Patents
Composition containing Berberis amurensis extracts for preventing the formation of biofilm of microorganism Download PDFInfo
- Publication number
- KR20190124074A KR20190124074A KR1020180048153A KR20180048153A KR20190124074A KR 20190124074 A KR20190124074 A KR 20190124074A KR 1020180048153 A KR1020180048153 A KR 1020180048153A KR 20180048153 A KR20180048153 A KR 20180048153A KR 20190124074 A KR20190124074 A KR 20190124074A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- barberry
- microorganism
- biofilm formation
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 244000005700 microbiome Species 0.000 title claims description 24
- 241001407301 Berberis amurensis Species 0.000 title abstract description 4
- 230000015572 biosynthetic process Effects 0.000 title description 9
- 230000032770 biofilm formation Effects 0.000 claims abstract description 35
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 33
- 201000001245 periodontitis Diseases 0.000 claims abstract description 15
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 14
- 208000007565 gingivitis Diseases 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 241001083847 Berberis Species 0.000 claims description 40
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 40
- 229940107588 barberry extract Drugs 0.000 claims description 38
- 239000000606 toothpaste Substances 0.000 claims description 17
- 229940034610 toothpaste Drugs 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000194025 Streptococcus oralis Species 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 239000002324 mouth wash Substances 0.000 claims description 9
- 229940051866 mouthwash Drugs 0.000 claims description 9
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 8
- 241000194026 Streptococcus gordonii Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 241001464887 Parvimonas micra Species 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 3
- 241001135221 Prevotella intermedia Species 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 17
- 208000006558 Dental Calculus Diseases 0.000 abstract description 11
- 230000008021 deposition Effects 0.000 abstract description 3
- 208000025157 Oral disease Diseases 0.000 abstract description 2
- 208000030194 mouth disease Diseases 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 10
- 241000194017 Streptococcus Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000002200 mouth mucosa Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- -1 anetol Chemical compound 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 208000024693 gingival disease Diseases 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000012128 staining reagent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000120 Artificial Saliva Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013588 oral product Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- PARMADWNFXEEFC-UHFFFAOYSA-N bamethan sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1 PARMADWNFXEEFC-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nutrition Science (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 매발톱나무 추출물을 포함하는 바이오필름 형성 억제 효능이 있는 조성물에 관한 것으로, 더욱 자세하게는 구강세균의 바이오필름 형성 억제 효과를 갖는 매발톱나무 추출물을 유효성분으로 포함하는 치태, 치석, 치은염 또는 치주염과 같은 구강질환의 예방 및 개선용 조성물에 관한 것이다.The present invention relates to a composition having an inhibitory effect on biofilm formation including barberry extract, and more particularly plaque, tartar, gingivitis or periodontitis comprising barberry extract having an inhibitory effect on biofilm formation of oral bacteria as an active ingredient. It relates to a composition for the prevention and improvement of oral diseases such as.
바이오필름(Biofilm)이란, 미생물에 의해 형성된 다양한 폴리머 물질로 싸인 미생물 복합체로 생물막 또는 균막이라고도 불린다. 이러한 바이오필름은 미생물이 다양한 환경에 적응하는데 도움을 주는 보호막의 역할을 하며 바이오필름 내의 균체들은 서로 대사(metabolism)을 공유하기도 하고, 유전자 전달(gene transfer)을 통해 생존에 유리한 성질들을 획득하기도 한다. 따라서 바이오필름을 형성한 균체들은 일반적인 부유균 상태로 존재할 때보다 가혹한 환경과 항생제에 대해 훨씬 강한 저항력을 가지며, 장기에 형성된 바이오필름은 다양한 병증을 야기한다. 이러한 병증이나 발병 위치를 예로 들면, 충치(dental caries), 치은염(gingivitis), 치주염(periodontitis), 중이염(otitis media), 인공후두(voice prostheses), 뇌수종(hydrocephalus hunts), 낭포성섬유증(cystic fibrosis), 심내막염(valvular endocarditis), 인공심장판막(prosthetic heart valves), 중심정맥관(central venous catheter), 인공고관절(prosthetic hip joint), 인공슬관절(prosthetic knee joint), 만성 세균성 전립선염(chronic bacterial prostatitis), 자궁내 장치(intrauterine devices), 요도관(urinarycatheter) 등을 들 수 있다.Biofilm is a microbial complex wrapped with various polymer materials formed by microorganisms, also called biofilm or biofilm. These biofilms serve as protective barriers to help microorganisms adapt to various environments, and the cells in the biofilm share metabolism with each other, and acquire properties for survival through gene transfer. . Therefore, the biofilm-forming cells have a much stronger resistance to harsh environments and antibiotics than when they are present in the form of ordinary suspended bacteria, and the biofilms formed in the organs cause various conditions. Examples of such conditions or locations include dental caries, gingivitis, periodontitis, otitis media, voice prostheses, hydrocephalus hunts, and cystic fibrosis. ), Valvular endocarditis, prosthetic heart valves, central venous catheter, prosthetic hip joint, prosthetic knee joint, chronic bacterial prostatitis , Intrauterine devices, urinary catheter, and the like.
한편, 구강은 약 1,000여종의 세균이 존재하는 것으로 알려져 있으며, 이에 서식하는 많은 세균은 구강 바이오필름을 형성한다. 그 중 초기 구강 바이오필름 형성과 관련된 세균으로는 스트렙토코커스 종(Streptococcus spp.)으로 알려져 있다. 이들 스트렙토코커스 종은 치아표면의 초기 부착균으로, 특히 스트렙토코커스 고도니(Streptococcus gordonii), 스트렙토코커스 오랄리스(Streptococcus oralis)는 치석의 원인이 되는 구강 바이오필름의 형성이 시작되는데 중요한 역할을 한다. 또한 포피로모나스 진지발리스(Porphyromonas gingivalis)는 치주염, 치은염과 같은 잇몸 질환을 유발하는 주요 원인균으로 알려져 있다. 따라서 치석 형성을 억제함에 있어 이들 균을 제어하고자 하는 노력이 지속되고 있다.On the other hand, oral cavity is known to exist about 1,000 kinds of bacteria, many bacteria inhabiting it forms the oral biofilm. Among the bacteria associated with the early oral biofilm formation is known as Streptococcus spp . These Streptococcus species are early adherent bacteria on the tooth surface, especially Streptococcus gordonii and Streptococcus oralis play an important role in the formation of oral biofilms that cause tartar. Porphyromonas gingivalis is also known as a major cause of gum disease such as periodontitis and gingivitis. Therefore, efforts to control these bacteria in suppressing tartar formation have continued.
치아 표면에 형성된 바이오필름에 타액 내의 칼슘이나 마그네슘 등의 금속 이온이 결합되면 석회화된 치석을 형성하게 된다. 치석이 적절하게 제거되지 못하면 치은염, 치주염과 같은 잇몸 질환을 야기하며 심각하게는 치아의 손실을 유발한다. 치주질환의 발생을 예방하기 위한 노력으로 클로로헥시딘 글루코네이트, 세틸피리디움 클로라이드, 생귀나린 및 트리클로산과 같은 항균제가 개발되어 양치약 및 치약과 같은 구강제품에 적용되어 왔으나, 아직까지도 치은염증의 발생은 근본적으로 예방하지 못하고 있는 실정이다. 또한 이러한 합성 항생제는 장기간 사용할 경우, 구강 내 점막을 자극할 뿐만 아니라, 정상균도 파괴시켜 오히려 구강 내 병원균에 대한 내성을 증가시키며, 치아착색 및 미각을 해치는 등의 인체에 대한 부작용이 크다. When metal ions such as calcium or magnesium in saliva bind to the biofilm formed on the tooth surface, calcified calculus is formed. If tartar is not removed properly, it can cause gum disease such as gingivitis and periodontitis, and seriously loss of teeth. In an effort to prevent the development of periodontal disease, antibacterial agents such as chlorohexidine gluconate, cetylpyridium chloride, guinealine and triclosan have been developed and applied to oral products such as toothpaste and toothpaste. Outbreaks are not fundamentally prevented. In addition, these synthetic antibiotics, when used for a long time, not only irritate the oral mucosa, but also destroy normal bacteria, but rather increase the resistance to oral pathogens, and have a great side effect on the human body such as hurting tooth coloring and taste.
따라서 합성 화합물을 사용하는 기존제품들의 문제점을 극복할 수 있는, 천연 항균제를 포함하는 치주질환 예방용 구강제품이 요구된다.Therefore, there is a need for oral products for preventing periodontal disease, including natural antimicrobial agents, which can overcome the problems of existing products using synthetic compounds.
매발톱나무(Berberis amurensis)는 구과목 주목과의 상록교목으로 우리나라 남부 지방 바닷가의 산에 서식한다. 열매, 뿌리껍질, 꽃을 약용으로 사용한다. 피부 보습 및 염증완화(대한민국 등록특허 10-1648466), 항 스트레스(대한민국 등록특허 10-1434449) 등의 효능도 보고된 바 있으나, 매발톱나무가 구강 치주 질환에 대하여 나타내는 효능에 대해서는 보고된 바가 없다. Barberry ( Berberis amurensis ) is an evergreen tree of the genus Yew, which lives in the mountains along the coast of southern Korea. Use fruit, root bark, and flowers for medicinal purposes. Efficacy of skin moisturizing and inflammation alleviation (Korea Patent Registration 10-1648466), anti-stress (Korea Patent Registration 10-1434449), etc. has been reported, but there is no report on the efficacy of barberry on oral periodontal disease.
이에 본 발명자는 매발톱나무 추출물을 유효성분으로 함유하여 치석침착과 치주 질환의 예방 또는 개선에 효능이 있는 구강 조성물을 제공하고자 본 발명을 안출하였다.Accordingly, the present inventors have devised the present invention to provide an oral composition containing barberry extract as an active ingredient, which is effective in preventing or improving tartar deposition and periodontal disease.
본 발명이 해결하고자 하는 과제는 상기한 바와 같이 종래 기술의 단점 및 문제점을 개선하기 위한 것으로서, 본 발명의 일측면은 매발톱나무 추출물을 함유하여 바이오필름 형성 억제용 조성물을 제공하는 것이다.The problem to be solved by the present invention is to improve the disadvantages and problems of the prior art as described above, one aspect of the present invention is to provide a composition for inhibiting biofilm formation containing barberry extract.
본 발명의 또 다른 목적은, 매발톱나무 추출물을 포함하는 치석침착과 치주질환의 예방 및 개선에 효과가 있는 구강 조성물을 제공하는 것이다.Still another object of the present invention is to provide an oral composition which is effective in preventing and improving tartar deposition and periodontal disease, including barberry extract.
그러나, 본 발명이 해결하고자 하는 과제는 이상에서 언급한 것들로 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the problem to be solved by the present invention is not limited to those mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.
상기 과제를 이루기 위하여 본 발명의 일 측면은 매발톱나무 줄기 추출물, 매발톱나무 잎 추출물, 매발톱나무 꽃 추출물, 매발톱나무 열매 추출물 및 매발톱나무 종자 추출물로 구성된 군으로부터 선택된 1 종 이상의 매발톱나무 추출물을 유효성분으로 포함하는 것을 특징으로 하는 미생물의 바이오필름 형성 억제용 조성물을 제공한다.One aspect of the present invention to achieve the above object is at least one barberry extract selected from the group consisting of barberry extract, barberry leaf extract, barberry flower extract, barberry fruit extract and barberry seed extract as an active ingredient It provides a composition for inhibiting biofilm formation of microorganisms comprising.
본 발명에서 상기 미생물은 스트렙토코커스 고도니(Streptococcus gordonii),스트렙토코커스 오랄리스(Streptococcus oralis), 포피로모나스 진지발리스(Porphyromonas gingivalis), 퓨소박테리움 뉴클레아텀(Fusobacterium nucleatum), 프레보텔라 인터메디아(Prevotella intermedia), 파비모나스 미크라(Parvimonasmicra; Peptostreptococcus micros) 및 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans; Actinobacillus actinomycetemcomitans)로 구성된 군에서 적어도 어느 하나를 포함하나, 이에 제한되지 않는다.In the present invention, the microorganisms are Streptococcus gordonii , Streptococcus oralis , Porphyromonas gingivalis , Fusobacterium nucleatum , Prebotela But not limited to at least one of the groups consisting of Prevotella intermedia , Parvimonasmicra; Peptostreptococcus micros , and Aggregatibacter actinomycetemcomitans; Actinobacillus actinomycetemcomitans .
상기 과제를 이루기 위하여 본 발명은, 치주질환 예방 및 개선용 기능성 식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a functional food composition for preventing and improving periodontal disease.
상기 과제를 이루기 위하여 본 발명의 다른 측면으로 상기 구강 조성물은 바이오필름 형성 억제에 효과적이기 때문에 치석, 치은염 및 치주염 등의 치주질환 예방 및 개선용 구강 조성물을 제공한다. 상기 구강 조성물은 치약류, 츄잉껌, 구강 청정제, 구강 세정제 및 구강 스프레이 중 선택된 어느 하나 이상의 제형을 가질 수 있다. In another aspect of the present invention, the oral composition is effective in inhibiting biofilm formation, thereby providing an oral composition for preventing and improving periodontal diseases such as tartar, gingivitis and periodontitis. The oral composition may have any one or more formulations selected from toothpaste, chewing gum, mouthwash, mouthwash and mouth spray.
본 발명에 따르면, 매발톱나무 추출물을 포함하는 미생물의 바이오필름 형성 억제용 조성물은, 구강세균에 대한 항균활성과 바이오필름 형성 억제 효과를 가짐으로써, 치석과 치은염, 치주염과 같은 치주질환을 예방 및 개선할 수 있다.According to the present invention, the composition for inhibiting biofilm formation of microorganisms comprising barberry extract has antimicrobial activity and biofilm formation inhibitory effect on oral bacteria, thereby preventing and improving periodontal diseases such as tartar, gingivitis and periodontitis. can do.
또한, 천연물질로 이루어져서 합성 물질에 의한 부작용이나 위험도가 없는 인체에 안전한 조성물을 제공할 수 있다.In addition, it is possible to provide a composition that is safe for the human body, which is made of natural materials and has no side effects or risks caused by the synthetic material.
또한, 인체에 안전하므로, 기능성 식품 조성물, 치약, 구강용 가글과 같이 인체에 직접 닿거나 심지어 인체에 들어가는 제품으로 다양하게 응용할 수 있다.In addition, because it is safe for the human body, such as functional food composition, toothpaste, oral gargle can be applied to a variety of products that directly touch or even enter the human body.
본 발명의 기술적 효과들은 이상에서 언급한 것들로 제한되지 않으며, 언급되지 않은 또 다른 기술적 효과들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The technical effects of the present invention are not limited to those mentioned above, and other technical effects that are not mentioned will be clearly understood by those skilled in the art from the following description.
도 1은 매발톱나무 잎 추출물을 처리하지 않은 것과 매발톱나무 잎 추출물을 처리한 것의 바이오필름 형성 양상을 나타낸 사진이다.
도 2는 매발톱나무 잎 추출물을 처리하지 않은 것과 매발톱나무 잎 추출물을 처리한 것의 하이드록시아파타이트 디스크에서의 바이오필름 형성 양상을 나타낸 그래프이다.
도 3은 매발톱나무 추출물을 처리하지 않은 것과 매발톱나무 잎 추출물을 처리한 것의 비수용성 글루칸 합성 양상을 나타낸 그래프이다.
도 4는 구강점막세포에 대한 매발톱나무 추출물의 세포 독성 실험 결과를 나타낸 그래프이다.1 is a photograph showing a biofilm formation aspect of the barberry leaf extract not treated and treated with barberry leaf extract.
FIG. 2 is a graph showing the biofilm formation of hydroxyapatite discs without treatment with barberry leaf extract and with treatment with barberry leaf extract.
Figure 3 is a graph showing the water-insoluble glucan synthesis aspect of not treated with barberry extract and treated with barberry leaf extract.
Figure 4 is a graph showing the cytotoxicity test results of barberry extract on oral mucosa cells.
이하 본 발명을 보다 상세히 설명한다. 다만, 이는 본 발명의 이해를 돕기 위하여 구체적으로 기재한 것뿐이며, 본 발명의 범위는 청구범위를 기초로 해석된다.Hereinafter, the present invention will be described in more detail. However, this is only specifically described to help the understanding of the present invention, the scope of the present invention is interpreted based on the claims.
본 발명은, 매발톱나무 줄기 추출물, 매발톱나무 잎 추출물, 매발톱나무 꽃 추출물, 매발톱나무 열매 추출물 및 매발톱나무 종자 추출물로 구성된 군으로부터 선택된 1 종 이상의 매발톱나무 추출물을 유효성분으로 포함하는 것을 특징으로 하는 미생물의 바이오필름 형성 억제용 조성물을 제공한다.The present invention is a microorganism comprising at least one barberry extract selected from the group consisting of barberry stem extract, barberry leaf extract, barberry flower extract, barberry fruit extract and barberry seed extract as an active ingredient It provides a composition for inhibiting biofilm formation.
상기 매발톱나무 추출물은 사용되는 부위에 따라 매발톱나무 줄기 추출물, 매발톱나무 잎 추출물, 매발톱나무 꽃 추출물, 매발톱나무 열매 추출물 및 매발톱나무 종자 추출물로 나눌 수 있다. The barberry extract may be divided into barberry stem extract, barberry leaf extract, barberry flower extract, barberry fruit extract and barberry seed extract depending on the portion used.
본 발명에서 "매발톱나무 줄기 추출물"은 매발톱나무 줄기를 추출 대상으로 하여 얻어지는 모든 형태의 추출물로서, 예를들어 식물 줄기에 직/간접적으로 열을 가해 얻는 진액 형태의 추출물, 살아있는 식물 줄기의 윗부분을 잘라 흘러나오는 진액 형태의 추출물, 식물을 유기용매, 또는 물로 추출하여 얻는 추출물, 식물 줄기를 연소시킬 때 기체를 냉각하여 얻는 추출물 등을 모두 포함하는 것이다.In the present invention, "barberry stem extract" is an extract of all forms obtained by extracting barberry trunks, for example, extracts in the form of essences obtained by applying heat directly or indirectly to the plant stem, the upper part of the living plant stem Extracts in the form of extracts from the essence, and extracts obtained by extracting the plant with an organic solvent or water, extracts obtained by cooling the gas when burning the plant stem, and the like.
본 발명에서 "매발톱나무 열매 추출물"은 유기 용매 또는 물을 사용하여 얻어지는 추출물과 매발톱나무 열매를 압착하여 얻어지는 진행 형태의 추출물, 용매 추출물을 감압하여 얻어지는 오일 추출물을 포함한다."Barberry fruit extract" in the present invention includes an extract obtained by using an organic solvent or water and the extract of the progressive form obtained by pressing the barberry fruit, oil extract obtained by depressurizing the solvent extract.
본 발명에서 "매발톱나무 종자 추출물"은, 유기 용매 또는 물을 사용하여 얻어진 추출물과, 매발톱나무 종자를 압착하여 얻어지는 진액 추출물, 또는 용매 추출물을 감압하여 얻어진 오일 추출물을 포함한다."Barberry seed extract" in the present invention includes an extract obtained by using an organic solvent or water, a essence extract obtained by pressing the barberry seeds, or an oil extract obtained by depressurizing a solvent extract.
본 발명에서 "매발톱나무 잎 추출물"은 유기 용매 또는 물 추출물을 의미한다."Barberry leaf extract" in the present invention means an organic solvent or water extract.
본 발명에서 "매발톱나무 꽃 추출물"은 유기 용매 또는 물 추출물을 의미한다."Barberry flower extract" in the present invention means an organic solvent or water extract.
예를 들어, 상기 매발톱나무 추출물은 각각의 줄기, 잎, 꽃, 열매 및 종자를 분쇄한 후 탄소수 1 내지 4의 알코올, 에틸아세테이트, 헥산, 클로로포름 등의 유기용매 및 물 또는 이들의 혼합용매로 추출된 추출물일 수 있다. For example, the barberry extract is pulverized each stem, leaf, flower, fruit and seed, and then extracted with an organic solvent such as alcohol having 1 to 4 carbon atoms, ethyl acetate, hexane, chloroform and water or a mixed solvent thereof. May be an extract.
가장 바람직한 추출물로는 매발톱나무 잎의 에탄올 추출물이 사용될 수 있다.The most preferred extract may be an ethanol extract of barberry leaves.
상기 추출물의 제조방법은 냉침 추출법, 온침추출법 또는 열 추출법 등이 사용될 수 있으며, 통상의 추출기기, 초음파 분쇄 추출기 또는 분획기를 이용할 수 있다.As the preparation method of the extract may be used, such as cold needle extraction method, hot needle extraction method or heat extraction method, it may be used a conventional extraction device, ultrasonic grinding extractor or fractionator.
또 다른 예에 의하면, 상기 매발톱나무 추출물은 상기 열매 및/또는 종자의 유기용매 추출물을 감압하여 오일로 만든 것을 사용할 수도 있다.According to another example, the barberry extract may be made of oil by reducing the organic solvent extract of the fruit and / or seed.
상기 제조된 추출물은 여과하거나 농축 또는 건조하여 용매를 제거할 수 있으며, 구체적으로 상기 여과는 여과지를 이용하거나 감압 여과기를 이용할 수 있으며, 상기 농축은 감압 농축기, 일예로 회전 증발기를 이용하여 감압 농축할 수 있고, 상기 건조는 일예로 동결 건조법으로 수행할 수 있다.The prepared extract may be filtered, concentrated or dried to remove the solvent. Specifically, the filtration may be performed using a filter paper or a vacuum filter, and the concentration may be concentrated under reduced pressure using a vacuum evaporator, for example, a rotary evaporator. The drying may be performed by freeze drying, for example.
본 발명에 따른 조성물은 미생물의 바이오필름 형성을 억제하는데 효과가 있다.The composition according to the present invention is effective in inhibiting biofilm formation of microorganisms.
여기서 "미생물"이란 본 발명의 조성물이 미생물의 바이오필름 형성을 억제하는데 특히 효능이있는 모든 세균, 진균, 효모 및 조류를 포함하는 개념이다. 따라서, 하기 실시예 및 실험예에서 직접적으로 바이오필름 형성 억제가 확인된 미생물 이외에도 당업자가 통상의 능력 범위 내에서 본 명세서가 개시한 바를 기초로 바이오필름 형성을 억제할 것으로 예상되고 확인될 수 있는 모든 미생물이 포함되는 것으로 이해되어야 한다.The term "microorganism" is a concept in which the composition of the present invention includes all bacteria, fungi, yeast and algae that are particularly effective in inhibiting biofilm formation of microorganisms. Thus, in addition to the microorganisms directly inhibited biofilm formation in the following Examples and Experimental Examples all those skilled in the art can be expected and confirmed to inhibit biofilm formation based on the disclosure herein within the scope of ordinary skill It is to be understood that microorganisms are included.
본 발명의 일 실시예에 의하면, 특히 스트렙토코커스 고도니(Streptococcus gordonii), 스트렙토코커스 오랄리스(Streptococcus oralis), 포피로모나스 진지발리스(Porphyromonas gingivalis), 퓨소박테리움 뉴클레아텀(Fusobacterium nucleatum), 프레보텔라 인터메디아(Prevotella intermedia), 파비모나스 미크라(Parvimonas micra; Peptostreptococcus micros) 및 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans; Actinobacillus actinomycetemcomitans)로 이루어진 군으로부터 선택된 1종 이상의 균의 바이오필름 형성 억제에 효과가 있다.According to one embodiment of the invention, in particular Streptococcus gordonii, Streptococcus oralis , Porphyromonas gingivalis , Fusobacterium nucleatum , Prevotella intermedia , Parvimonas micra; Peptostreptococcus micros , and Aggregatibacter actinomycetemcomitans; Actinobacillus actinomycetemcomitans; It is effective in suppressing biofilm formation.
본 발명에 따른 매발톱나무 추출물은 바이오필름 형성을 억제할 수 있는 한 그 사용되는 제품에 따라 적절하게 사용될 수 있다. 통상적으로 본 발명에 따른 매발톱나무 추출물은 이 조성물을 포함하여 미생물의 바이오필름 형성 억제 효능을 나타내는 조성물에 대하여 그 조성물의 전체 중량을 기준으로 0.001 ~ 5.0 중량%, 바람직하게는 0.2~2중량%로 포함될 수 있다.The barberry extract according to the present invention may be suitably used depending on the product used as long as it can suppress the biofilm formation. Typically, barberry extract according to the present invention is 0.001 to 5.0% by weight, preferably 0.2 to 2% by weight, based on the total weight of the composition with respect to the composition including the composition exhibiting the inhibitory effect of biofilm formation May be included.
상기 조성물은 치주질환 유발균에 대한 항균 활성을 가지며, 치아 표면에 바이오필름이 형성되는 것을 억제함으로써 치석 생성을 억제하여 치은염 또는 치주염 질환의 예방 및 개선 효과가 우수하다. The composition has an antimicrobial activity against periodontal disease-causing bacteria and inhibits the formation of tartar by inhibiting the formation of biofilm on the surface of the tooth, and is excellent in preventing and improving gingivitis or periodontitis disease.
본 발명에서 치은염(gingivitis)는 구강 점막의 일부인 잇몸에 염증이 발생하는 것으로, 종창, 발적, 통증 또는 국소 열감의 증세가 나타나고, 심한 경우는, 궤양 또는 괴저가 발생할 수 있는 질환을 의미한다.In the present invention, gingivitis is an inflammation of the gum which is a part of the oral mucosa, and symptoms of swelling, redness, pain, or localized heat appear, and in severe cases, a disease in which an ulcer or necrosis may occur.
본 발명에서 치주염(periodontitis)는 치주위염이라고도 하며, 잇몸과 골성조직에 주로 발명하는 질병으로 만성 감염증이 될 경우, 세포 조직이 파괴됨으로서, 치아를 잃게되는 치주질환을 의미한다. In the present invention, periodontitis (periodontitis) is also referred to as periodontitis, a disease mainly invented in the gums and bone tissue when chronic infection, cell tissue is destroyed, means a periodontal disease that loses teeth.
본 발명에 따른 미생물의 바이오필름 형성 억제용 조성물은 인간을 포함하는 동물에 직접 적용할 수 있다. The composition for inhibiting biofilm formation of microorganisms according to the present invention can be directly applied to animals including humans.
상기 본 발명에 따른 미생물의 바이오필름 형성 억제용 조성물은 매발톱나무 추출물외에 사용방법 및 사용 목적에 따라 다양한 성분들을 더 포함할 수 있다.The composition for inhibiting biofilm formation of microorganisms according to the present invention may further include various components depending on the method of use and purpose of use, besides the barberry extract.
본 발명의 일 실시예에 의하면, 매발톱나무 추출물을 포함하는 기능성 식품 조성물을 제공할 수 있으며, 예를 들어 식품 또는 음료등을 들 수 있다.According to one embodiment of the present invention, it is possible to provide a functional food composition comprising barberry extract, for example, food or drink.
본 명세서에서 식품이란 영양소를 한가지 이상 함유하고 있는 천연물 또는 가공물을 의미하며, 바람직하게는 어느 정도 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며 통상적 의미로서, 식품, 식품 첨가제, 건강 기능성 식품 및 음료를 모두 포함하고자 하는 의도이며, 각종 식품, 음료, 껌, 캔디, 차, 비타민 복합제, 기능성 식품등이 있다. In the present specification, the food means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through a processing process to some extent, and as a general meaning, food, food additives, health functional foods. And it is intended to include all drinks, there are various foods, beverages, gum, candy, tea, vitamin complex, functional food and the like.
본 발명의 일 실시예에 의하면, 치주염 또는 치은염 예방 및 치료를 위한 조성물을 제공한다. 이러한 조성물의 예로는 치약, 양치용액, 구강세척제, 치약 크림 등이 있다.According to one embodiment of the present invention, a composition for preventing and treating periodontitis or gingivitis is provided. Examples of such compositions include toothpaste, toothpaste solution, mouthwash, toothpaste cream and the like.
본 발명에 따른 조성물이 치약인 경우, 매발톱나무 추출물외에 연마제, 점결제, 보습제, 발포제, 감미료, 미백제 또는 향미제를 추가로 포함할 수 있다.When the composition according to the present invention is a toothpaste, in addition to the barberry extract, it may further include an abrasive, a binder, a moisturizer, a foaming agent, a sweetener, a whitening agent or a flavoring agent.
본 발명에 따른 조성물이 페이스트 상 조성물일 경우에는 상기 점결제는 가라기닌, 각종 점증용 셀룰로오스 유도체, 잔탄검, 트라가칸트검 등의 검류, 폴리비닐알콜, 폴리아크릴산 나트륨, 폴리아크릴산/말레인산 공중합체, 카르복시비닐 폴리머 등의 합성 고분자 유도체 등의 유기계 점결제와 실리카, 라포나이트 등의 무기계 점결제 등을 단독 또는 복합적으로 사용할 수 있다.When the composition according to the present invention is a paste-like composition, the caking agent is a tarpaulin, such as tarpaulin, various cellulose derivatives, xanthan gum, and tragacanth gum, polyvinyl alcohol, sodium polyacrylate, and polyacrylic acid / maleic acid copolymer. And organic binders such as synthetic polymer derivatives such as carboxyvinyl polymer, and inorganic binders such as silica and laponite can be used alone or in combination.
상기 보습제는 솔비톨, 글리세린, 에틸렌글리콜, 프로필렌글리콜, 폴리에테르글리콜, 폴리프로필렌 글리콜 등이 사용될 수 있다.The moisturizing agent may be used such as sorbitol, glycerin, ethylene glycol, propylene glycol, polyether glycol, polypropylene glycol and the like.
상기 감미료는 수크로오즈, 락토오즈, 말토오즈, 크실리톨, 나트륨시클라메이트, 사카린나트륨, 스테비오사이드, 아스파탐 등이 사용될 수 있다. The sweetener may be used sucrose, lactose, maltose, xylitol, sodium cyclate, sodium saccharin, stevioside, aspartame and the like.
상기 향료는 페퍼민트, 멘톨, 아네톨, 오이게놀, 리모넨, 시트로네놀, 알파터피네올, 살리실메틸, 시네올, 리나롤, 이틸리나롤, 바닐린, 티몰, 스피아민트유, 세지유, 로즈마리유, 계피유등을 사용할 수 있다. The fragrance is peppermint, menthol, anetol, eugenol, limonene, citronenol, alpha terpineol, salicylmethyl, cineol, linalol, italylinaol, vanillin, thymol, spearmint oil, sage oil, Rosemary oil and cinnamon oil can be used.
본 발명에 따른 조성물이 양치 용액인 경우에는 통상적인 용제에 매발톱나무 추출물을 혼합하고, 양치용액으로 제형화하여 제조할 수 있으며, 하루 2 내지 10회 구강을 세척하여 치주염 또는 치은염과 같은 치주질환을 예약 및 치료할 수 있다. When the composition according to the present invention is a fern solution, it can be prepared by mixing the barberry extract in a conventional solvent, formulated as a fern solution, and washes the mouth 2 to 10 times a day for periodontal disease such as periodontitis or gingivitis. Can be booked and treated.
본 발명에 따른 조성물이 치약 크림인 경우에는 물과 보습제를 포함하는 액체, 겔화제 또는 수불용성 광택제, 감미료, 향료 등을 추가로 포함할 수 있다.When the composition according to the present invention is a toothpaste cream, it may further include a liquid, a gelling or water-insoluble varnish, sweeteners, flavoring and the like containing water and a moisturizing agent.
본 발명에 따른 조성물이 구강 세척제인 경우에는, 치약 담체, 상세하게는 비독성 알코올을 더 포함할 수 있다.When the composition according to the present invention is a mouthwash, it may further comprise a toothpaste carrier, in particular a nontoxic alcohol.
상기 조성물은 상기 성분들외에도, 사용하고자 하는 목적에 따라 적절하게 영양제, 비타민, 전해질, 풍미제, 착색제, 충진제, 알긴산 및 그의 염, 유기산, 증점제, pH 조절제, 풍미제, 안정화제, 방부제, 글리세린, 알코올, 탄산화제 등을 더 포함할 수 있다. In addition to the above components, the composition may be suitably used according to the purpose to be used, nutritional supplements, vitamins, electrolytes, flavoring agents, coloring agents, fillers, alginic acid and salts thereof, organic acids, thickeners, pH adjusting agents, flavoring agents, stabilizers, preservatives, glycerin , Alcohol, carbonation agent, and the like may be further included.
본 발명의 일 실시예에 따라서, 상기 매발톱나무 추출물을 함유하는 본 발명의 조성물은 치약류, 츄잉껌, 구강청정제, 구강세정제 및 구강스프레이 등의 제형으로 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다.According to an embodiment of the present invention, the composition of the present invention containing the barberry extract may be prepared by using a formulation such as toothpaste, chewing gum, mouthwash, mouthwash and mouth spray, but is not limited thereto.
이하, 본 발명을 구체적으로 설명하기 위해 실험예 및 실시예를 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실험예는 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 실험예와 실시예에 한정되는 것으로 해석되어서는 안된다. 본 발명의 실험예 및 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공되는 것이다.Hereinafter, the present invention will be described in detail with reference to experimental examples and examples. However, the experimental examples according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the experimental examples and examples described below. Experimental examples and examples of the present invention are provided to more completely explain the present invention to those skilled in the art.
제조예 1 : 매발톱나무 추출물 제조Preparation Example 1: Preparation of Barberry Extract
건조된 매발톱나무 잎을 분쇄하여 2배량의 에탄올에 침지시킨 상태로 초음파 장치에 30분간 노출시켰다. 24시간 침지 후 여과지에 거른 다음 회전감압농축기로 용매를 제거하여 추출물을 제조하였다.The dried barberry leaves were crushed and exposed to an ultrasonic apparatus for 30 minutes while being immersed in twice the amount of ethanol. After immersion for 24 hours, the filter was filtered and then extract was prepared by removing the solvent with a rotary pressure reducer.
실험예 1 : 구강 균주 및 배양조건Experimental Example 1: Oral Strains and Culture Conditions
균주는 KCTC 생물자원센터에서 스트렙토코커스 고도니(Streptococcus gordonii), 스트렙토코커스 오랄리스(Streptococcus oralis), 포피로모나스 진지발리스(Porphyromonas gingivalis) 균을 분양받아 사용하였다. Strains were used to obtain Streptococcus gordonii , Streptococcus oralis , and Porphyromonas gingivalis from KCTC BRC.
상기 분양받은 스트렙토코커스 고도니(Streptococcus gordonii), 스트렙토코커스 오랄리스(Streptococcus oralis), 포피로모나스 진지발리스(Porphyromonas gingivalis) 균을 5 ug/mL hemin과 1 ug/ml vitamin K를 포함하는 BHI(brain heart infusion) broth 배지에 접종한 후 이를 37 ℃, 혐기조건에서 정치배양하여 실험에 사용하였다. Streptococcus gordonii , Streptococcus oralis , and Porphyromonas gingivalis fungi ( Brep ) containing 5 ug / mL hemin and 1 ug / ml vitamin K brain heart infusion) and then inoculated in broth medium was used in the experiment by stationary culture at 37 ℃, anaerobic conditions.
실험예 2 : 항균활성 확인Experimental Example 2: Confirmation of antimicrobial activity
매발톱나무 추출물의 구강균에 대한 항균활성을 측정하기 위해 MIC(minimal inhibitory concentration) 테스트를 진행하였다.Minimal inhibitory concentration (MIC) tests were conducted to determine the antimicrobial activity of barberry extracts against oral bacteria.
96 well-plate에 최종 혼합액이 200 uL가 되도록 약 5x10^5 CFU/mL 농도의 세균 배양액에 각 농도에 따른 추출물을 처리하였다. 추출물의 경우 감압 농축된 매발톱나무 추출물을 DMSO에 50 mg/mL의 농도로 녹인 것을 사용하여, 멸균된 액체배지로 500, 250, 125, 62.5, 31.25 ug/mL 농도가 되도록 희석해서 사용하도록 했다.Extracts according to each concentration were treated in a bacterial culture solution at a concentration of about 5x10 ^ 5 CFU / mL so that the final mixture was 200 uL on a 96 well-plate. In the case of the extract, the barberry extract concentrated under reduced pressure was dissolved in DMSO at a concentration of 50 mg / mL, and diluted to a concentration of 500, 250, 125, 62.5, and 31.25 ug / mL in a sterilized liquid medium.
세균 배양액, 추출물을 포함하는 상기 혼합액을 처리한 96-웰 플레이트를 37 ℃, 혐기조건에서 24~72 시간 배양하였다.The 96-well plate treated with the mixed solution containing the bacterial culture solution and the extract was incubated at 37 ° C. under anaerobic conditions for 24 to 72 hours.
항균활성의 판정은 추출물 미처리 대조군 대비 실험군의 흡광도를 샘플 처리 직후와 24~72시간 배양 후 마이크로플레이트 리더를 이용하여 600 nm에서 흡광도를 측정하여 그 변화 값을 계산, 비교하여 진행하였다.The antimicrobial activity was determined by comparing the absorbance of the experimental group with the extract-treated control group immediately after sample treatment and incubation at 600 nm using a microplate reader after incubation for 24 to 72 hours.
(ug/mL)MIC
(ug / mL)
상기 표 1은 스트렙토코커스 고도니, 스트렙토코커스 오랄리스, 포피로모나스 진지발리스 단일 균주, 복합 균주에 대한 MIC 값을 나타낸 것으로, 매발톱나무 추출물이 스트렙토코커스 고도니와 스트렙토코커스 오랄리스 균에 대하여 각각 250, 62.5 ug/mL 이상의 농도에서 항균 활성을 나타내는 것을 확인하였다.Table 1 shows the MIC values for Streptococcus gornea, Streptococcus oralis, Popiromonas jinjivalis single strain, and multiple strains, and the barberry extract was 250 for Streptococcus gornea and Streptococcus oralis, respectively. , 62.5 ug / mL or more was confirmed to exhibit an antimicrobial activity.
실험예 3 : 바이오필름 형성 억제능 측정-MicroplateExperimental Example 3: Measurement of inhibitory ability of biofilm formation-Microplate
매발톱나무 추출물의 바이오필름 형성 억제능을 확인하기 위해 마이크로 플레이트를 이용한 실험을 진행하였다.In order to confirm the inhibitory ability of biofilm formation of barberry extract, an experiment using a microplate was conducted.
96 well-plate에 스트렙토코커스 고도니, 스트렙토코커스 오랄리스, 포피로모나스 진지발리스 복합균 약 5x10^5 CFU/mL, 매발톱나무 추출물을 각 200, 100, 50, 25, 10 ug/mL, 1% 수크로오스를 포함하는 액체배지 200 uL을 처리하였다. 상기 96 웰 플레이트를 37 ℃, 혐기조건에서 72시간 동안 정치 배양하였다.Streptococcus gordon, Streptococcus oralis, Poppyromonas jinbaris complex, about 5x10 ^ 5 CFU / mL,
72시간 배양 후, 배지를 제거하고 각 웰에 정제수 200 uL를 가하여 부유균과 바이오필름에 약하게 결합되어 있는 균들을 제거하는 작업을 3회 반복하였다. 이후, 각 웰에 0.1% crystal violet 염색 시약을 200 uL씩 첨가하여 15분간 상온에서 반응시켰다. 15분 후 잔여 염색약을 제거하기 위해 정제수를 이용하여 3회 washing하였다. 염색된 바이오필름을 상온에서 건조시킨 뒤 각 웰의 바이오필름 생성 정도를 확인하였다.After incubation for 72 hours, the medium was removed and 200 uL of purified water was added to each well to remove suspended bacteria and bacteria that are weakly bound to the biofilm. Thereafter, 200 uL of 0.1% crystal violet staining reagent was added to each well, followed by reaction at room temperature for 15 minutes. After 15 minutes, the resultant was washed three times using purified water to remove residual dye. After drying the dyed biofilm at room temperature, the degree of biofilm formation in each well was confirmed.
도 1에 나타난 바와 같이, 본 발명의 매발톱나무 추출물을 처리한 실험군에서는 대조군과 비교하여 200 ppm 이상의 농도에서 바이오필름 형성을 억제하였음을 확인하였다.As shown in Figure 1, it was confirmed that the experimental group treated with the barberry extract of the present invention inhibited biofilm formation at a concentration of 200 ppm or more compared to the control.
실험예 4 : 바이오필름 형성 억제능 측정-하이드록시아파타이트 디스크(Hydroxyapatite disc)Experimental Example 4: Measurement of inhibitory ability of biofilm formation-Hydroxyyapatite disc
매발톱나무 추출물의 바이오필름 형성 억제능을 확인하기 위한 하이드록시아파타이트 디스크 실험을 진행하였다.A hydroxyapatite disc experiment was conducted to confirm the inhibitory ability of biofilm formation of barberry extract.
24 well-plate에 스트렙토코커스 고도니, 스트렙토코커스 오랄리스, 포피로모나스 진지발리스 복합균 약 5x10^5 CFU/ml, 매발톱나무 추출물을 각 200, 100, 50, 25 ug/mL, 1% sucrose를 포함하는 액체배지 1 mL을 처리하고, 인공침(artificial saliva)으로 코팅된 하이드록시아파타이트(hydroxyapatite) 디스크를 침지시킨다. 상기 24 well-plate를 37 ℃, 혐기조건에서 3일간 정치배양하였다. In a well-plate, Streptococcus gordon, Streptococcus oralis, Poppyromonas jinjivalis complex, about 5x10 ^ 5 CFU / ml, each of the barberry extracts 200, 100, 50, 25 ug / mL, 1% sucrose Treating 1 mL of the liquid medium containing, and immersed hydroxyapatite disk coated with artificial saliva (artificial saliva). The 24 well-plates were incubated for 3 days at 37 ° C. under anaerobic conditions.
72시간 배양 후, 배지를 제거하고 각 웰에 정제수 1 mL를 가하여 부유균과 바이오필름에 약하게 결합되어 있는 균들을 제거하는 작업을 3회 반복하였다. 이후, 각 웰에 0.1% crystal violet 염색 시약을 1 mL씩 첨가하여 15분간 상온에서 반응시켰다. 15분 후 잔여 염색 시약을 제거하기 위해 정제수를 이용하여 3회 washing하였다. 염색된 바이오필름을 상온에서 건조시킨 뒤 95% 에탄올을 가하여 충분히 반응시켰다. 염색약이 녹아 나온 에탄올 100 uL를 96-웰 플레이트에 옮겨 마이크로플레이트 리더를 이용하여 550 nm에서 흡광도를 측정하였다.After 72 hours of incubation, the medium was removed, and 1 mL of purified water was added to each well to remove the bacteria that are weakly bound to the floating bacteria and the biofilm. Thereafter, 1 mL of 0.1% crystal violet staining reagent was added to each well, followed by reaction at room temperature for 15 minutes. After 15 minutes, the resultant was washed three times with purified water to remove residual staining reagent. The dyed biofilm was dried at room temperature and then reacted sufficiently by adding 95% ethanol. 100 uL of ethanol from which the dye was dissolved was transferred to a 96-well plate, and the absorbance was measured at 550 nm using a microplate reader.
도 2에 나타난 바와 같이, 본 발명의 추출물을 처리한 실험군에서는 대조군과 비교하여 50 ug/mL 이상의 농도에서 바이오필름 형성을 억제하였음을 확인하였다.As shown in Figure 2, it was confirmed that the experimental group treated with the extract of the present invention inhibited biofilm formation at a concentration of 50 ug / mL or more compared to the control.
실험예 5 : 비수용성 글루칸 합성 저해능 측정Experimental Example 5: Determination of Insoluble Glucan Synthesis Inhibition
스트렙토코커스 고도니를 BHI 액체배지에 24시간 배양한 후, 원심분리(6,000 g, 4 ℃, 15분)하여 상층액을 취하였다. 스트렙토코커스 고도니 상층액에 추출물을 각 농도별로 처리함과 동시에 수크로오스의 농도가 1%가 되도록 하였다.Streptococcus goni was incubated in BHI liquid medium for 24 hours, followed by centrifugation (6,000 g, 4 ° C, 15 minutes) to obtain a supernatant. The extracts were treated with each concentration of Streptococcus goni supernatant and the concentration of sucrose was 1%.
37℃에서 18시간 배양한 후 동량의 메탄올을 첨가하여 반응을 정지시킨 후 원심분리(6,000 g, 4 ℃, 15분)하여 정제수로 2회 washing하고, 70% 에탄올로 1회 washing하여 비수용성 글루칸 pellet을 얻었다.After 18 hours of incubation at 37 ° C, the reaction was stopped by addition of the same amount of methanol, followed by centrifugation (6,000 g, 4 ° C, 15 minutes), washing twice with purified water, washing once with 70% ethanol, and water-insoluble glucan. A pellet was obtained.
잔여 용매를 건조시킨 후 pellet에 75% H2SO4에 anthrone을 2 mg/mL으로 용해시킨 시약을 처리하여 100 ℃에서 15분간 반응시켰다. 이후 반응물의 온도가 상온으로 떨어질 때까지 기다린 후 마이크로플레이트 리더를 이용하여 620 nm에서 흡광도를 측정하였다.After drying the residual solvent, the pellet was treated with a reagent in which anthrone was dissolved at 2 mg / mL in 75% H 2 SO 4 , and reacted at 100 ° C. for 15 minutes. After waiting until the temperature of the reactant drops to room temperature, the absorbance was measured at 620 nm using a microplate reader.
그 결과, 도 3과 같이 매발톱나무 추출물의 비수용성 글루칸 합성억제활성은 매발톱나무 추출물을 처리하지 않은 것과 비교하여 100, 50, 25,10 ug/mL에서 각각 29.7%, 29.7%, 36.1%, 78.2%의 비수용성 글루칸 생성율을 나타내었다.As a result, as shown in FIG. 3, the water-insoluble glucan synthesis inhibitory activity of barberry extract was 29.7%, 29.7%, 36.1%, and 78.2 at 100, 50, 25, 10 ug / mL, respectively, compared to the untreated barberry extract. A water insoluble glucan production rate of% is shown.
실험예 6 : 구강점막세포에 대한 세포독성Experimental Example 6: Cytotoxicity to Oral Mucosa Cells
구강점막세포에 대한 매발톱나무 추출물의 독성을 측정하기 위해 MTT 실험을 진행하였다.MTT experiments were conducted to determine the toxicity of barberry extracts on oral mucosa cells.
hTERT-OME(immortalized human oral mucosal epithelial cell)를 96 웰 플레이트에 약 1x10^4 cells/well로 처리한 다음 RPMI-1640, 10% FBS, 1% penicillin-streptomycin 배지에서 37℃, 5% CO2조건으로 24시간 동안 배양하였다. 24시간 후 이전 배양에 사용된 배지를 제거하고 배지에 200, 100, 50, 25, 12.5 ug/mL로 희석한 매발톱나무 추출물을 처리하여 37℃, 5% CO2에서 24시간 반응시켰다. 처리 후 각 웰 당 5 mg/mL MTT 용액을 20 uL 씩 첨가하여 37℃, 5% CO2에서 3시간 동안 반응시켰다. 반응 후 상등액을 모두 제거하고 DMSO 150 uL 씩 첨가하여 상온에서 10분간 반응시킨 후 마이크로플레이트 리더를 이용하여 540 nm에서 흡광도를 측정하였다.hTERT-OME (immortalized human oral mucosal epithelial cells) were treated in 96 well plates at approximately 1x10 ^ 4 cells / well, then at 37 ° C and 5% CO2 in RPMI-1640, 10% FBS, 1% penicillin-streptomycin medium. Incubated for 24 hours. After 24 hours, the medium used for the previous culture was removed, and the barberry extract diluted to 200, 100, 50, 25, and 12.5 ug / mL was treated in the medium and reacted at 37 ° C. and 5% CO 2 for 24 hours. After treatment, 20 uL of 5 mg / mL MTT solution was added to each well, followed by reaction at 37 ° C. and 5% CO 2 for 3 hours. After the reaction, all of the supernatant was removed, and 150 μL of DMSO was added thereto, followed by reaction at room temperature for 10 minutes. The absorbance was measured at 540 nm using a microplate reader.
그 결과, 도 4와 같이 매발톱나무 추출물은 200 ug/mL 이하에서 구강 점막세포에 대하여 세포독성을 나타내지 않았다.As a result, as shown in Figure 4, barberry extract did not show cytotoxicity to oral mucosal cells at 200 ug / mL or less.
실시예 1 : 매발톱나무 추출물을 함유하는 치약 조성물 제조Example 1 Preparation of Toothpaste Composition Containing Barberry Extract
실시예-치약 조성물을 하기 표 2와 같은 성분 및 조성비로 제조하였다. Example-Toothpaste composition was prepared with the components and composition ratios shown in Table 2.
구강 조성물 중 치약 조성물의 제조순서는 습윤제인 비결정성 소르비톨액에 카르복시메틸셀룰로오스나트륨, 사카린나트륨 등 분말 소량 성분을 분산시키고 정제수로 묽힌 다음 혼합기에서 1차 혼합하고, 그 다음에 실리카 및 탄산칼슘 등의 연마제를 넣고 2차 혼합했다. 그리고 마지막으로 기포제, 안정제, 향료 등을 넣고 3차 혼합함으로써 치약 조성물을 제조하였다.The procedure for preparing the toothpaste composition in the oral composition is to disperse a small amount of powder components such as sodium carboxymethylcellulose and sodium saccharin in an amorphous sorbitol liquid as a humectant, dilute with purified water, and then mix in a mixer first, and then, such as silica and calcium carbonate, etc. The abrasive was added and mixed secondly. And finally, a toothpaste composition was prepared by adding a foaming agent, a stabilizer, a perfume, and the like, and tertiary mixing.
실시예의 치약 조성물은 바이오필름 생성을 억제하는 최소 농도인 200 ug/mL의 매발톱나무 추출물을 포함하여 제조하였다.Example toothpaste composition was prepared containing 200 ug / mL barberry extract, the minimum concentration that inhibits the production of biofilm.
상기의 실험들로부터 매발톱나무 추출물이 치주질환의 근본원인인 바이오필름 형성의 초기 단계에서 중요한 역할을 하는 스트렙토코커스 고도니(Streptococcus gordonii), 스트렙토코커스 오랄리스(Streptococcus oralis)와 잇몸질환을 유발시키는 포피로모나스 진지발리스(Porphyromonas gingivalis)의 세균막 형성을 억제시킴으로써 치주염, 치은염 등 잇몸질환을 예방 또는 개선하는 천연소재임을 확인하였다.From these experiments, barberry extracts play an important role in the early stages of biofilm formation, the root cause of periodontal disease, Streptococcus gordonii , Streptococcus oralis and foreskin causing gum disease. By inhibiting the formation of bacterial membranes of Porphyromonas gingivalis , it was confirmed that it is a natural material that prevents or improves gum disease such as periodontitis and gingivitis.
Claims (7)
상기 미생물의 바이오필름 억제용 조성물이 치주염 또는 치은염 예방 또는 개선용 건강기능식품 조성물인 것을 특징으로 하는 미생물의 바이오필름 형성 억제용 조성물.The method according to any one of claims 1 to 4,
The composition for inhibiting biofilm formation of a microorganism, wherein the composition for inhibiting biofilm of the microorganism is a health functional food composition for preventing or improving periodontitis or gingivitis.
상기 미생물의 바이오필름 억제용 조성물이 치주질환 예방 및 개선용 구강 조성물인 것을 특징으로 하는 미생물의 바이오필름 형성 억제용 조성물.The method according to any one of claims 1 to 4,
Composition for inhibiting biofilm formation of the microorganism, characterized in that the composition for inhibiting the biofilm of the microorganism is an oral composition for preventing and improving periodontal disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180048153A KR20190124074A (en) | 2018-04-25 | 2018-04-25 | Composition containing Berberis amurensis extracts for preventing the formation of biofilm of microorganism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180048153A KR20190124074A (en) | 2018-04-25 | 2018-04-25 | Composition containing Berberis amurensis extracts for preventing the formation of biofilm of microorganism |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190124074A true KR20190124074A (en) | 2019-11-04 |
Family
ID=68578329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180048153A KR20190124074A (en) | 2018-04-25 | 2018-04-25 | Composition containing Berberis amurensis extracts for preventing the formation of biofilm of microorganism |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190124074A (en) |
-
2018
- 2018-04-25 KR KR1020180048153A patent/KR20190124074A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4948044B2 (en) | Plaque formation inhibitor or anti-cariogenic agent | |
KR102408893B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
KR101104548B1 (en) | Composite of toothpaste antibiosis | |
KR102636026B1 (en) | Composition for prevention or trreatment of dental disease comprising an extract of Thalictrum aquilegiifolium | |
KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
KR20190124073A (en) | Composition containing Juniperus rigida siebold and Zucc extracts for preventing the formation of biofilm of microorganism | |
KR102572961B1 (en) | Compositions for preventing, improving or treating periodontal disease containing dendropanax morbifera lev. extracts | |
KR101881636B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
KR20030089047A (en) | Composition for enhancing oral health | |
KR102540804B1 (en) | Composition containing Torreya nucifera extracts for preventing the formation of biofilm of mmicroorgaism | |
KR20190124074A (en) | Composition containing Berberis amurensis extracts for preventing the formation of biofilm of microorganism | |
KR20170142740A (en) | Composition for treating or preventing oral diseases comprising natural complex | |
KR20190124075A (en) | Oral Composition containing Salix graciliglans Nakai extracts | |
KR102415612B1 (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
KR20190043357A (en) | Dental composition for antiplaque and antigingivity | |
KR102283663B1 (en) | Antimicrobial composition comprising extracts of herb | |
KR102260939B1 (en) | Composition for prevention or treatment of dental disease comprising an extract of Matteuccia struthiopteris | |
KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
KR20200114022A (en) | Oral composition containing Polygalae Radix extracts | |
KR20200114023A (en) | Oral composition containing Nux-Vomica extracts | |
KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
KR20240078208A (en) | Composition for teeth whitening and antibacterial for oral microorganisms comprising apple extract | |
KR102580941B1 (en) | Composition for prevention or treatment of oral disease comprising Qucercetin 3-glucoside | |
KR102417082B1 (en) | Composition for prevention or treatment of oral disease comprising Celosia argentea Extract | |
KR20200002209A (en) | Composition for prevention or treatment of dental disease comprising an extract of Clinopodium chinense |